HPV-driven oropharyngeal cancer burden in Paris and its region (ILE DE FRANCE) from 1981 TO 2021
France has the sixth highest incidence of oropharyngeal cancer (OPC) in Europe, but the epidemiological impact of high-risk HPV (HR-HPV) remains poorly documented. The objective of our study was to assess the proportion of OPCs caused by HR-HPV in Paris, and its suburbs, over the four past decades....
Gespeichert in:
| Veröffentlicht in: | Cancer epidemiology 2024-08, Vol.91, p.102603, Article 102603 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 102603 |
| container_title | Cancer epidemiology |
| container_volume | 91 |
| creator | Mirghani, Haitham Tendron, Alexandre Auperin, Anne Casiraghi, Odile Classe, Marion Badoual, Cécile Legoupil, Clémence Puech, Julien Veyer, David Dalstein, Véronique Pere, Hélène Gorphe, Philippe |
| description | France has the sixth highest incidence of oropharyngeal cancer (OPC) in Europe, but the epidemiological impact of high-risk HPV (HR-HPV) remains poorly documented. The objective of our study was to assess the proportion of OPCs caused by HR-HPV in Paris, and its suburbs, over the four past decades. This area accounts for almost one-fifth of the total population of France.
OPCs diagnosed in 1981, 1986, 1991, 1996, 2001, 2006, 2011, 2016 and 2020/2021 in two of the main referral cancer centers for HNCs in Paris and its suburbs were retrieved from the tumor biobanks. HPV status was determined by p16-staining and HPV-DNA detection. Samples were considered HPV-driven if both assays were positive. Results were compared to the French cancer registry data.
Samples from 697 OPC patients were assessed (including 82 % of all samples diagnosed in 2001, 2006, 2011, 2016, 2021). The proportion of HPV-driven cases rose from 2.7 % to 53 % between 1981 and 2021. HPV16 was the dominant genotype during the study period. Of patients with HPV-driven OPC, 81 % were male and 42 % were smokers versus 80 % and 92 % in their HPV-negative counterparts. The age of OPC patients increased significantly, during the study period, independent of their HPV status
The proportion of HPV-driven OPCs has significantly increased in Paris and its suburbs, during the last four decades. OPCs has become the 2nd predominant type of head and neck cancer, in France. This may be linked to the rise in HPV-driven cases and the decrease of tobacco and alcohol consumption in men.
•France has one of the highest rates of head and neck cancers in Europe.•HPV-driven cases rose from 2.7 % to 53 % between 1981 and 2021 in Paris region.•63 % of HPV-positive cancer patients are current or former smoker.•Age of OPC patients increased significantly during the study period. |
| doi_str_mv | 10.1016/j.canep.2024.102603 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04633204v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1877782124000821</els_id><sourcerecordid>3070839116</sourcerecordid><originalsourceid>FETCH-LOGICAL-c301t-d830e57596f29c1bbe60ad1211ae9bfe64dab836c10e0b57f9d7828bff73a8853</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEoqXwC5CQJS7tIctMnDjOgcNq2XYrrWiFCuJmnHjSepWNt_ZmJf49TlP2wIGTrZlnPt55k-Q9wgwBxafNrNE97WYZZHmMZAL4i-QUZVmmpeQ_Xx7_GZ4kb0LYAAiBWLxOTrisAEGWp8mv1e2P1Hh7oJ4573YP2v_u70l3LDZvyLN68CbmbM9utbeB6d4wuw_M0711PTu_Xi_ZlyW7_Db_ulhesNa7LcNKIru7YXEzfJu8anUX6N3ze5Z8v1zeLVbp-ubqejFfpw0H3KdGcqCiLCrRZlWDdU0CtMEMUVNVtyRyo2vJRYNAUBdlW5koTNZtW3ItZcHPkoup74Pu1M7bbRSinLZqNV-rMQa54DyD_ICRPZ_YnXePA4W92trQUNfFe7ohKA4lSF4hioh-_AfduMH3UclIVRLyshiH84lqvAvBU3vcAEGNZqmNejJLjWapyaxY9eG591BvyRxr_roTgc8TQPFwB0tehcZStMVYT81eGWf_O-APMOSghA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3079804755</pqid></control><display><type>article</type><title>HPV-driven oropharyngeal cancer burden in Paris and its region (ILE DE FRANCE) from 1981 TO 2021</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><creator>Mirghani, Haitham ; Tendron, Alexandre ; Auperin, Anne ; Casiraghi, Odile ; Classe, Marion ; Badoual, Cécile ; Legoupil, Clémence ; Puech, Julien ; Veyer, David ; Dalstein, Véronique ; Pere, Hélène ; Gorphe, Philippe</creator><creatorcontrib>Mirghani, Haitham ; Tendron, Alexandre ; Auperin, Anne ; Casiraghi, Odile ; Classe, Marion ; Badoual, Cécile ; Legoupil, Clémence ; Puech, Julien ; Veyer, David ; Dalstein, Véronique ; Pere, Hélène ; Gorphe, Philippe</creatorcontrib><description>France has the sixth highest incidence of oropharyngeal cancer (OPC) in Europe, but the epidemiological impact of high-risk HPV (HR-HPV) remains poorly documented. The objective of our study was to assess the proportion of OPCs caused by HR-HPV in Paris, and its suburbs, over the four past decades. This area accounts for almost one-fifth of the total population of France.
OPCs diagnosed in 1981, 1986, 1991, 1996, 2001, 2006, 2011, 2016 and 2020/2021 in two of the main referral cancer centers for HNCs in Paris and its suburbs were retrieved from the tumor biobanks. HPV status was determined by p16-staining and HPV-DNA detection. Samples were considered HPV-driven if both assays were positive. Results were compared to the French cancer registry data.
Samples from 697 OPC patients were assessed (including 82 % of all samples diagnosed in 2001, 2006, 2011, 2016, 2021). The proportion of HPV-driven cases rose from 2.7 % to 53 % between 1981 and 2021. HPV16 was the dominant genotype during the study period. Of patients with HPV-driven OPC, 81 % were male and 42 % were smokers versus 80 % and 92 % in their HPV-negative counterparts. The age of OPC patients increased significantly, during the study period, independent of their HPV status
The proportion of HPV-driven OPCs has significantly increased in Paris and its suburbs, during the last four decades. OPCs has become the 2nd predominant type of head and neck cancer, in France. This may be linked to the rise in HPV-driven cases and the decrease of tobacco and alcohol consumption in men.
•France has one of the highest rates of head and neck cancers in Europe.•HPV-driven cases rose from 2.7 % to 53 % between 1981 and 2021 in Paris region.•63 % of HPV-positive cancer patients are current or former smoker.•Age of OPC patients increased significantly during the study period.</description><identifier>ISSN: 1877-7821</identifier><identifier>ISSN: 1877-783X</identifier><identifier>EISSN: 1877-783X</identifier><identifier>DOI: 10.1016/j.canep.2024.102603</identifier><identifier>PMID: 38901087</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult ; Aged ; Alcohol ; Cancer ; Cancer(s) ; Epidemiology ; Female ; France ; Genotypes ; Head & neck cancer ; Human papillomavirus ; Human papillomavirus (HPV) ; Humans ; Immunization ; Incidence ; Laboratories ; Laryngeal cancer ; Life Sciences ; Male ; Males ; Middle Aged ; Neoplasm(s) ; Oral/oropharynx/oropharyngeal ; Oropharyngeal cancer ; Oropharyngeal Neoplasms - epidemiology ; Oropharyngeal Neoplasms - virology ; Papillomavirus Infections - complications ; Papillomavirus Infections - epidemiology ; Papillomavirus Infections - virology ; Paris - epidemiology ; Population ; Prevalence ; Smoking ; Suburban areas ; Suburbs ; Throat cancer ; Tobacco ; Tonsil/tonsillar ; Trends ; Tumors</subject><ispartof>Cancer epidemiology, 2024-08, Vol.91, p.102603, Article 102603</ispartof><rights>2024 Elsevier Ltd</rights><rights>Copyright © 2024 Elsevier Ltd. All rights reserved.</rights><rights>2024. Elsevier Ltd</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c301t-d830e57596f29c1bbe60ad1211ae9bfe64dab836c10e0b57f9d7828bff73a8853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/3079804755?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,778,782,883,3539,27911,27912,45982,64370,64372,64374,72224</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38901087$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-reims.fr/hal-04633204$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Mirghani, Haitham</creatorcontrib><creatorcontrib>Tendron, Alexandre</creatorcontrib><creatorcontrib>Auperin, Anne</creatorcontrib><creatorcontrib>Casiraghi, Odile</creatorcontrib><creatorcontrib>Classe, Marion</creatorcontrib><creatorcontrib>Badoual, Cécile</creatorcontrib><creatorcontrib>Legoupil, Clémence</creatorcontrib><creatorcontrib>Puech, Julien</creatorcontrib><creatorcontrib>Veyer, David</creatorcontrib><creatorcontrib>Dalstein, Véronique</creatorcontrib><creatorcontrib>Pere, Hélène</creatorcontrib><creatorcontrib>Gorphe, Philippe</creatorcontrib><title>HPV-driven oropharyngeal cancer burden in Paris and its region (ILE DE FRANCE) from 1981 TO 2021</title><title>Cancer epidemiology</title><addtitle>Cancer Epidemiol</addtitle><description>France has the sixth highest incidence of oropharyngeal cancer (OPC) in Europe, but the epidemiological impact of high-risk HPV (HR-HPV) remains poorly documented. The objective of our study was to assess the proportion of OPCs caused by HR-HPV in Paris, and its suburbs, over the four past decades. This area accounts for almost one-fifth of the total population of France.
OPCs diagnosed in 1981, 1986, 1991, 1996, 2001, 2006, 2011, 2016 and 2020/2021 in two of the main referral cancer centers for HNCs in Paris and its suburbs were retrieved from the tumor biobanks. HPV status was determined by p16-staining and HPV-DNA detection. Samples were considered HPV-driven if both assays were positive. Results were compared to the French cancer registry data.
Samples from 697 OPC patients were assessed (including 82 % of all samples diagnosed in 2001, 2006, 2011, 2016, 2021). The proportion of HPV-driven cases rose from 2.7 % to 53 % between 1981 and 2021. HPV16 was the dominant genotype during the study period. Of patients with HPV-driven OPC, 81 % were male and 42 % were smokers versus 80 % and 92 % in their HPV-negative counterparts. The age of OPC patients increased significantly, during the study period, independent of their HPV status
The proportion of HPV-driven OPCs has significantly increased in Paris and its suburbs, during the last four decades. OPCs has become the 2nd predominant type of head and neck cancer, in France. This may be linked to the rise in HPV-driven cases and the decrease of tobacco and alcohol consumption in men.
•France has one of the highest rates of head and neck cancers in Europe.•HPV-driven cases rose from 2.7 % to 53 % between 1981 and 2021 in Paris region.•63 % of HPV-positive cancer patients are current or former smoker.•Age of OPC patients increased significantly during the study period.</description><subject>Adult</subject><subject>Aged</subject><subject>Alcohol</subject><subject>Cancer</subject><subject>Cancer(s)</subject><subject>Epidemiology</subject><subject>Female</subject><subject>France</subject><subject>Genotypes</subject><subject>Head & neck cancer</subject><subject>Human papillomavirus</subject><subject>Human papillomavirus (HPV)</subject><subject>Humans</subject><subject>Immunization</subject><subject>Incidence</subject><subject>Laboratories</subject><subject>Laryngeal cancer</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Males</subject><subject>Middle Aged</subject><subject>Neoplasm(s)</subject><subject>Oral/oropharynx/oropharyngeal</subject><subject>Oropharyngeal cancer</subject><subject>Oropharyngeal Neoplasms - epidemiology</subject><subject>Oropharyngeal Neoplasms - virology</subject><subject>Papillomavirus Infections - complications</subject><subject>Papillomavirus Infections - epidemiology</subject><subject>Papillomavirus Infections - virology</subject><subject>Paris - epidemiology</subject><subject>Population</subject><subject>Prevalence</subject><subject>Smoking</subject><subject>Suburban areas</subject><subject>Suburbs</subject><subject>Throat cancer</subject><subject>Tobacco</subject><subject>Tonsil/tonsillar</subject><subject>Trends</subject><subject>Tumors</subject><issn>1877-7821</issn><issn>1877-783X</issn><issn>1877-783X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kU1v1DAQhiMEoqXwC5CQJS7tIctMnDjOgcNq2XYrrWiFCuJmnHjSepWNt_ZmJf49TlP2wIGTrZlnPt55k-Q9wgwBxafNrNE97WYZZHmMZAL4i-QUZVmmpeQ_Xx7_GZ4kb0LYAAiBWLxOTrisAEGWp8mv1e2P1Hh7oJ4573YP2v_u70l3LDZvyLN68CbmbM9utbeB6d4wuw_M0711PTu_Xi_ZlyW7_Db_ulhesNa7LcNKIru7YXEzfJu8anUX6N3ze5Z8v1zeLVbp-ubqejFfpw0H3KdGcqCiLCrRZlWDdU0CtMEMUVNVtyRyo2vJRYNAUBdlW5koTNZtW3ItZcHPkoup74Pu1M7bbRSinLZqNV-rMQa54DyD_ICRPZ_YnXePA4W92trQUNfFe7ohKA4lSF4hioh-_AfduMH3UclIVRLyshiH84lqvAvBU3vcAEGNZqmNejJLjWapyaxY9eG591BvyRxr_roTgc8TQPFwB0tehcZStMVYT81eGWf_O-APMOSghA</recordid><startdate>202408</startdate><enddate>202408</enddate><creator>Mirghani, Haitham</creator><creator>Tendron, Alexandre</creator><creator>Auperin, Anne</creator><creator>Casiraghi, Odile</creator><creator>Classe, Marion</creator><creator>Badoual, Cécile</creator><creator>Legoupil, Clémence</creator><creator>Puech, Julien</creator><creator>Veyer, David</creator><creator>Dalstein, Véronique</creator><creator>Pere, Hélène</creator><creator>Gorphe, Philippe</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>202408</creationdate><title>HPV-driven oropharyngeal cancer burden in Paris and its region (ILE DE FRANCE) from 1981 TO 2021</title><author>Mirghani, Haitham ; Tendron, Alexandre ; Auperin, Anne ; Casiraghi, Odile ; Classe, Marion ; Badoual, Cécile ; Legoupil, Clémence ; Puech, Julien ; Veyer, David ; Dalstein, Véronique ; Pere, Hélène ; Gorphe, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c301t-d830e57596f29c1bbe60ad1211ae9bfe64dab836c10e0b57f9d7828bff73a8853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alcohol</topic><topic>Cancer</topic><topic>Cancer(s)</topic><topic>Epidemiology</topic><topic>Female</topic><topic>France</topic><topic>Genotypes</topic><topic>Head & neck cancer</topic><topic>Human papillomavirus</topic><topic>Human papillomavirus (HPV)</topic><topic>Humans</topic><topic>Immunization</topic><topic>Incidence</topic><topic>Laboratories</topic><topic>Laryngeal cancer</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Males</topic><topic>Middle Aged</topic><topic>Neoplasm(s)</topic><topic>Oral/oropharynx/oropharyngeal</topic><topic>Oropharyngeal cancer</topic><topic>Oropharyngeal Neoplasms - epidemiology</topic><topic>Oropharyngeal Neoplasms - virology</topic><topic>Papillomavirus Infections - complications</topic><topic>Papillomavirus Infections - epidemiology</topic><topic>Papillomavirus Infections - virology</topic><topic>Paris - epidemiology</topic><topic>Population</topic><topic>Prevalence</topic><topic>Smoking</topic><topic>Suburban areas</topic><topic>Suburbs</topic><topic>Throat cancer</topic><topic>Tobacco</topic><topic>Tonsil/tonsillar</topic><topic>Trends</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mirghani, Haitham</creatorcontrib><creatorcontrib>Tendron, Alexandre</creatorcontrib><creatorcontrib>Auperin, Anne</creatorcontrib><creatorcontrib>Casiraghi, Odile</creatorcontrib><creatorcontrib>Classe, Marion</creatorcontrib><creatorcontrib>Badoual, Cécile</creatorcontrib><creatorcontrib>Legoupil, Clémence</creatorcontrib><creatorcontrib>Puech, Julien</creatorcontrib><creatorcontrib>Veyer, David</creatorcontrib><creatorcontrib>Dalstein, Véronique</creatorcontrib><creatorcontrib>Pere, Hélène</creatorcontrib><creatorcontrib>Gorphe, Philippe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Cancer epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mirghani, Haitham</au><au>Tendron, Alexandre</au><au>Auperin, Anne</au><au>Casiraghi, Odile</au><au>Classe, Marion</au><au>Badoual, Cécile</au><au>Legoupil, Clémence</au><au>Puech, Julien</au><au>Veyer, David</au><au>Dalstein, Véronique</au><au>Pere, Hélène</au><au>Gorphe, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HPV-driven oropharyngeal cancer burden in Paris and its region (ILE DE FRANCE) from 1981 TO 2021</atitle><jtitle>Cancer epidemiology</jtitle><addtitle>Cancer Epidemiol</addtitle><date>2024-08</date><risdate>2024</risdate><volume>91</volume><spage>102603</spage><pages>102603-</pages><artnum>102603</artnum><issn>1877-7821</issn><issn>1877-783X</issn><eissn>1877-783X</eissn><abstract>France has the sixth highest incidence of oropharyngeal cancer (OPC) in Europe, but the epidemiological impact of high-risk HPV (HR-HPV) remains poorly documented. The objective of our study was to assess the proportion of OPCs caused by HR-HPV in Paris, and its suburbs, over the four past decades. This area accounts for almost one-fifth of the total population of France.
OPCs diagnosed in 1981, 1986, 1991, 1996, 2001, 2006, 2011, 2016 and 2020/2021 in two of the main referral cancer centers for HNCs in Paris and its suburbs were retrieved from the tumor biobanks. HPV status was determined by p16-staining and HPV-DNA detection. Samples were considered HPV-driven if both assays were positive. Results were compared to the French cancer registry data.
Samples from 697 OPC patients were assessed (including 82 % of all samples diagnosed in 2001, 2006, 2011, 2016, 2021). The proportion of HPV-driven cases rose from 2.7 % to 53 % between 1981 and 2021. HPV16 was the dominant genotype during the study period. Of patients with HPV-driven OPC, 81 % were male and 42 % were smokers versus 80 % and 92 % in their HPV-negative counterparts. The age of OPC patients increased significantly, during the study period, independent of their HPV status
The proportion of HPV-driven OPCs has significantly increased in Paris and its suburbs, during the last four decades. OPCs has become the 2nd predominant type of head and neck cancer, in France. This may be linked to the rise in HPV-driven cases and the decrease of tobacco and alcohol consumption in men.
•France has one of the highest rates of head and neck cancers in Europe.•HPV-driven cases rose from 2.7 % to 53 % between 1981 and 2021 in Paris region.•63 % of HPV-positive cancer patients are current or former smoker.•Age of OPC patients increased significantly during the study period.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>38901087</pmid><doi>10.1016/j.canep.2024.102603</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1877-7821 |
| ispartof | Cancer epidemiology, 2024-08, Vol.91, p.102603, Article 102603 |
| issn | 1877-7821 1877-783X 1877-783X |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04633204v1 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE; ProQuest Central UK/Ireland |
| subjects | Adult Aged Alcohol Cancer Cancer(s) Epidemiology Female France Genotypes Head & neck cancer Human papillomavirus Human papillomavirus (HPV) Humans Immunization Incidence Laboratories Laryngeal cancer Life Sciences Male Males Middle Aged Neoplasm(s) Oral/oropharynx/oropharyngeal Oropharyngeal cancer Oropharyngeal Neoplasms - epidemiology Oropharyngeal Neoplasms - virology Papillomavirus Infections - complications Papillomavirus Infections - epidemiology Papillomavirus Infections - virology Paris - epidemiology Population Prevalence Smoking Suburban areas Suburbs Throat cancer Tobacco Tonsil/tonsillar Trends Tumors |
| title | HPV-driven oropharyngeal cancer burden in Paris and its region (ILE DE FRANCE) from 1981 TO 2021 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T04%3A41%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HPV-driven%20oropharyngeal%20cancer%20burden%20in%20Paris%20and%20its%20region%20(ILE%20DE%20FRANCE)%20from%201981%20TO%202021&rft.jtitle=Cancer%20epidemiology&rft.au=Mirghani,%20Haitham&rft.date=2024-08&rft.volume=91&rft.spage=102603&rft.pages=102603-&rft.artnum=102603&rft.issn=1877-7821&rft.eissn=1877-783X&rft_id=info:doi/10.1016/j.canep.2024.102603&rft_dat=%3Cproquest_hal_p%3E3070839116%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3079804755&rft_id=info:pmid/38901087&rft_els_id=S1877782124000821&rfr_iscdi=true |